Spinal Anesthesia Provides Longer Administration Time for Postoperative Intravesical Chemotherapy after TUR-B Operation

Abstract

<b><i>Purpose:</i></b> The aim of this study was to investigate the tolerability of postoperative early intravesical chemotherapy session after transurethral resection of the bladder tumor (TUR-B) according to the different anesthesia types. <b><i>Methods:</i></b> The study was conducted between February 2017 and June 2020. Patients who were given intravesical mitomycin (MMC) 40 mg after TUR-B were included. Patients’ risk categories (low, medium, and high) were determined according to the European Association of Urology (EAU) risk stratification system based on the tumor number, size (&#x3c;3 and ≥3 cm), T stage (Ta and T1), and grade (low and high). Patients were divided into 2 groups according to the applied anesthesia technique as group S (spinal) and group G (general). The patients’ visual analog scale (VAS) scores were recorded every 30 min for 2 h after urethral clamping. The patients’ pain scores were recorded using the VAS questionnaire form at 30th (VAS1), 60th (VAS2), 90th (VAS3), and 120th (VAS4) min after the urethral clamping. Requirement of analgesic, urethral clamp removal time, total instillation time, and discharged urine volume were recorded. Complications and complication grade (1–5) were recorded according to the Clavien-Dindo system. <b><i>Results:</i></b> A total of 232 consecutive patients who received intravesical MMC were included. Sociodemographic characteristics of group S (<i>n</i> = 113) and group G (<i>n</i> = 119) were similar (<i>p</i> &#x3c; 0.05). There were no significant differences in tumor size, number of tumors, concomitant CIS, and T stage in both groups (<i>p</i> &#x3e; 0.05). High-grade tumors were higher in group S (23.9 vs. 11%; <i>p</i> = 0.008). Requirement of analgesic (53.9 vs. 91.5%; <i>p</i> = 0.00) and termination of therapy &#x3c;60′ (2 vs. 26%; <i>p</i> = 0.00) and &#x3c;120′ (32.7 vs. 76.4%; <i>p</i> = 0.00) were significantly lower in group S. The mean instillation time (108.05 ± 19.40 vs. 85.67 ± 24.66 min; <i>p</i> = 0.00) was found significantly higher for group S. In group G, mean VAS1–4 scores were significantly higher than in group S (<i>p</i> &#x3c; 0.05). Linear correlation analyses showed that the VAS score is correlated with the instillation time (<i>p</i> &#x3c; 0.05). The rates of minor (I–III) (7 vs. 8%; <i>p</i> = 0.706) and major (IV–V) (0.9 vs. 1.6%; <i>p</i> = 0.590) complications were similar in both groups. <b><i>Conclusion:</i></b> The patients’ tolerability of intravesical MMC treatment can be improved by spinal anesthesia. It provides longer instillation time and less pain during intravesical chemotherapy.